If You Invested in Nexentis Technologies Inc (NXTS)
Looking for the current price? See the NXTS quote & overviewWhat $1,000 or $10,000 in NXTS Would Be Worth Now
Real historical value by amount invested and how long ago| If you invested | 1 year ago | 5 years ago | 10 years ago | Since Feb 26, 2026 |
|---|---|---|---|---|
| $1,000 | — | — | — | $214 -79% |
| $10,000 | — | — | — | $2,136 -79% |
Based on real historical closing prices, dividend- and split-adjusted, through the latest market close. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for NXTS$1,000 Investment Over Time
NXTS vs S&P 500Year-by-Year Returns
NXTS annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2026 | $7.21 | $1.54 | -78.6% | -78.6% |
About Nexentis Technologies Inc
Pharmaceutical Preparations · NASDAQ
Nexentis Technologies Inc. is a Nasdaq-listed operating company focused on biotechnology drug discovery and solar energy asset investments. The company describes itself as a drug discovery company that also invests in solar energy assets using a Ready to Build business model. Its common stock trades on the Nasdaq Capital Market under the symbol NXTS, and the company is incorporated in Nevada with corporate operations identified in Neve Yarak, Israel.
The company’s biotechnology activity is conducted through its wholly owned subsidiary, MitoCareX Bio Ltd. MitoCareX is focused on mitochondrial drug discovery, including therapeutic programs for inflammatory metabolic diseases and cancer that target specific metabolic pathways. Its proprietary algorithm platform, MITOLINE™, is a sequence analysis and alignment algorithm designed to prepare mitochondrial carrier proteins of the SLC25 family for 3D homology modeling. The platform is intended to address the lack of solved three-dimensional structures for many human mitochondrial carriers by aligning and annotating amino acid sequences and residues for comparative modeling.
Nexentis also reports an investment focus in solar energy assets based on the RTB model, which refers to projects that are ready to build. In addition, the company controls approximately 98% of Save Foods Ltd., an Israeli company focused on post-harvest treatment technologies designed to reduce pathogen contamination in fruits and vegetables.
The company’s public-company record includes capital-structure actions and shareholder approvals. In April 2026, Nexentis effected a one-for-seven reverse stock split of its common stock, after which the shares continued trading on Nasdaq under the NXTS symbol with a new CUSIP number. Its proxy and current-report disclosures also cover stockholder voting matters, Nasdaq Marketplace Rule 5635(d) equity-issuance approvals, material agreements, and amendments affecting common-stock rights.
Frequently Asked Questions
Nexentis Technologies Inc investment returns
How much would $1,000 invested in Nexentis Technologies Inc be worth today?
Limited historical data is available for NXTS. The stock has been trading since 2026-02-26.
Has Nexentis Technologies Inc outperformed the S&P 500?
Comparison data requires at least 10 years of trading history. Use the calculator above to compare NXTS performance over available time periods.
What is Nexentis Technologies Inc's average annual return?
Your Privacy is Protected
This calculator sends the symbol, date, and amount you enter to our server so we can fetch historical market data and render the result. We do not save those entries as a portfolio or account, but standard web server logs may still record the page request.
For informational and educational purposes only — not investment advice.
